Cargando…
Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis
BACKGROUND: Beta-interferon (IFN-β) and glatiramer acetate (GA) have been evaluated in people with clinically isolated syndrome (CIS) with the aim to delay a second clinical attack and a diagnosis of clinically definite multiple sclerosis (CDMS). We systematically reviewed trials evaluating the shor...
Autores principales: | Armoiry, X., Kan, A., Melendez-Torres, G. J., Court, R., Sutcliffe, P., Auguste, P., Madan, J., Counsell, C., Clarke, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937891/ https://www.ncbi.nlm.nih.gov/pubmed/29356977 http://dx.doi.org/10.1007/s00415-018-8752-8 |
Ejemplares similares
-
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
por: Melendez-Torres, G. J., et al.
Publicado: (2018) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018) -
Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015) -
Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015) -
Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
por: Rojas-Morales, Emmanuel, et al.
Publicado: (2019)